LIMARIN
Manufacturer Details
SERUM INSTITUTE
Compositions:
Silymarin 70mg/140mg capsules,
Silymarin 35mg/5ml suspension,
|
Strength
|
Rate
|
Packing Style
|
|
70mg
|
77.00
|
10s capsules
|
|
140mg
|
118.20
|
10a cappsules
|
|
35mg/ 5ml
|
103.90
|
100ml suspension
|
List of Related Indications:
List Of Drugs:
- Silymarin - Hepatobiliary agent- (June 1995)
Indication Type Description:
Drug Interaction:
None reported.
Indication:
Chronic active hepatitis
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Silymarin Hepatoprotective June 1995
Adverse Reaction:
Occasional laxative effect.
Contra-Indications:
H/O hypersensitivity,pregnancy and lactation.
Special precautions:
Safety in pregnancy, lactation, and in children not established.
Dosages/ Overdosage Etc:
Date of Approval - June 1995
Indication-
Chronic active hepatitis
Dosage-
70mg 2- 3 times daily Severe cases (serum bilirubin ) over 10mg- 140mg 2- 3 times daily for 6 weeks or as required
